Adamed Sp. Z O.o.

Adamed Pharma S.a.

Krzysztof Kazimierz Lemke

Jerzy Szczepan Pieczykolan

Sebastian Dominik Pawlak

Bartłomiej Żerek

Bartlomiej Zerek

Sebastian Pawlak

Bartlomiej Maciej Zerek

A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.

Anticancer fusion protein comprising TRAIL and interferon

The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases.

Anticancer fusion protein comprising trail

Growing community of inventors

Gdynia, Poland

Krzysztof Kazimierz Lemke